Blue light-controlled drug-releasing implants
The inability to use high-energy blue/UV light as the signal for light-triggered on-demand drug delivery is due to a formidable physiological barrier. This makes red light the only alternative. However, red light has intrinsically lower energy and limited value in photochemical reactions because the photocleavage of covalent bonds typically requires UV light. The EU-funded PADRE project will use blue/UV light to trigger and precisely control on-demand drug-releasing implants. The project will use light generated through photon upconversion or integrated light sources. The first method will allow pioneering, effective red-to-blue/UV triplet-triplet annihilation upconversion in a hydrogel environment. The second will enable light generation by a co-implanted light source.
Fields of science
Call for proposal
See other projects for this call
Funding SchemeERC-COG - Consolidator Grant